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ABSTRACT 
We have combined two peptide library-screening systems, exploiting the benefits 
offered by both to select novel antagonistic agents of cJun. CIS display is an in vitro 
cell-free system that allows very large libraries (≤1014) to be interrogated. However, 
affinity-based screening conditions can poorly reflect those relevant to therapeutic 
application, particularly for difficult intracellular targets, and can lead to false 
positives. In contrast, an in cellulo screening system such as the Protein-fragment 
Complementation Assay (PCA) selects peptides with high target affinity while 
additionally profiling for target-specificity, protease resistance, solubility and lack of 
toxicity in a more relevant context. A disadvantage is the necessity to transform cells, 
limiting library sizes that can be screened to ≤106. However, by combining both cell-
free and cell-based systems, we isolated a peptide (CPW) from a ~1010 member 
library, which forms a highly stable interaction with cJun (Tm 63 °C, Kd 750 nM, ΔG -
8.2 kcal/mol) using the oncogenic transcriptional regulator AP-1 as our exemplar 
target.  In contrast, CIS display alone, selected a peptide with low affinity for cJun (Tm 
34 °C, Kd 25 μM, ΔG -6.2 kcal/mol), highlighting the benefit of CIS→PCA. Furthermore, 
increased library size with CIS→PCA allows the freedom to introduce non-canonical 
options, such as interfacial aromatics, and solvent exposed options that may allow 
the molecule to explore alternative structures and interact with greater affinity and 
efficacy with the target. CIS→PCA therefore offers significant potential as a peptide-
library screening platform by synergistically combining the relative attributes of 
either assay to generate therapeutically interesting compounds that may otherwise 
not be identified.  
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INTRODUCTION 
Peptide libraries represent a valuable source of potential inhibitors for disease-
related protein-protein interactions (PPIs), such as the oncogenic basic-region zipper 
(bZIP) Activator Protein-1 (AP-1) system1-3, where smaller more drug-like molecules 
lack the requisite number of interacting moieties to be effective PPI modulators. 
Randomised peptide libraries offer huge functional diversity with respect to the range 
and combination of amino acid side chain physicochemical properties, interactions, 
and structures that can be achieved. Library screening also has the advantage over 
rational antagonist design in that affinity for the target is not dependent on 
comprehensive a priori knowledge of the most favourable peptide–target interactions 
4. 
To antagonise AP-1, a small number of direct inhibitory peptides have been 
previously derived. Earlier efforts generated peptides and proteins ranging from 46 to 
approximately 300 residues through native component protein truncation/mutation 5-
10. Later, Protein-fragment Complementation Assay (PCA) 11 and phage display 12 
screening of small libraries (62,000 – 140,000 peptides) generated 37 residue 
antagonists. More recently, a 42 residue antagonist of the cJun component of AP-1 1 
has been designed based on a scoring algorithm derived from peptide interaction 
microarray data 13. Collectively, these peptides have demonstrated antagonism of AP-
1 formation in vitro, and in several cases inhibition of oncogenic transformation when 
transfected and expressed 7, 10. However, the higher molecular weight antagonists risk 
suffering from many of the common shortcomings that prevent therapeutic 
administration 14, 15. Peptides benefit by containing a reduced number of protease 
recognition sites and immune epitopes. In addition, they are more economical to 
produce and are easier to modify for cell penetration 16, 17. Thus, derivation of short 
peptidic AP-1 antagonists is an attractive approach towards the development of 
peptide-based modulatory agents for cancer therapy. 
To create antagonists, known peptide binders can be truncated; however, even 
for parent molecules that have high affinity for the target such as the nanomolar FosW–
cJun interaction 11, binding affinity and structural propensity can become rapidly lost. 
An alternative strategy is to reduce entropic penalty to binding through helix constraint 
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18, 19, or iteratively optimise the primary sequence of peptides to compensate for the 
loss of interaction points with the target. This goal is most easily and effectively 
achieved using expansive library selection systems. 
To derive antagonists of high target affinity and favourable therapeutic-like 
properties, in cellulo library selection systems have the advantage of screening for 
target binders in an environment that mimics that in which therapeutic agents are 
required to function. However, such systems suffer from the requirement for 
transformation/transfection of cells with library-encoded DNA. This limits the library 
diversity that can be screened 4. In contrast, cell-free in vitro systems select peptides 
under less stringent conditions that do not replicate those within the cell, but have a 
major advantage in their ability to screen much larger peptide libraries to allow much 
greater exploration of physicochemical, functional and structural peptide space. 
Another in vitro selection limitation is the possibility that secondary selection pressures 
will enrich peptides that bind non-specifically to other components in the system, such 
as magnetic beads, streptavidin, biotin or polypropylene plates20. 
In contrast, in cellulo systems such as bacterial PCA (e.g. based on reactivation 
of murine DHFR (mDHFR) upon library–target interaction) has the benefit of selecting 
peptides for therapeutic properties such as target-specificity, aggregation- and 
protease-resistance, cytosolic stability and non-toxicity 21. In addition, PCA is rapidly 
and easily performed due to the robustness of bacterial growth. However, the 
diversities of libraries in PCA-based selection are usually restricted to ≤106 peptides 11. 
Of the in vitro systems, CIS display 22 combines facile, rapid screening using highly 
manipulable selection pressures and coverage of similar theoretical library diversities 
(≤1014 peptides) 23 to mRNA display 24, ribosome display 25, or phage display 
alternatives 26. Furthermore, CIS display is based on DNA-encoding of libraries, and so 
avoids stability issues with mRNA-encoding of libraries in mRNA and ribosome displays. 
Previously, cell-based and in vitro methods have been used to screen peptide 
libraries. However, it was unknown whether such systems could be complementary. 
The distinct overlap between their advantages and disadvantages led to the hypothesis 
that successful combination of in vitro and in vivo systems could exploit the benefits of 
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both to isolate high affinity peptides from hugely diverse libraries with concomitant 
intracellular refinement of drug-like properties (Figure 1). 
A PCA-derived 37 residue cJun antagonist known as FosW 11 was previously 
truncated to 32 residues, with PCA further used to re-optimise affinity. The resulting 
antagonist, 4hFosW, displayed a binding affinity (ΔG) within 11 % of FosW whilst being 
13 % shorter (45 nM to 480 nM) 27. In contrast, the loss of binding affinity by simple 
truncation of the FosW sequence by the same amount was measured to be 43 % 19. 
This supports the hypothesis that library selection for more optimal residues to could 
be successful. Furthermore, by utilising CIS-display to screen a much larger library 
(≤1014 peptides) than used to derive 4hFosW (49,152 peptides), it was anticipated that 
even higher affinities might be possible despite further truncation. Here we describe 
the novel combination of CIS display and PCA screening systems (“CIS→PCA”) with the 
aim of creating a more powerful system than either approach alone. In doing so the 
major aim was to exploit synergy between the two systems, and ultimately generate 
therapeutically interesting peptides capable of modulating PPIs in therapeutically 
relevant settings.  
 
RESULTS 
Library design 
A highly diverse mixed-length peptide library was constructed of various 
lengths through a modular synthesis of DNA corresponding to individual heptads 
repeats (a-b-c-d-e-f-g). This was expected to represent a coiled coil (CC) library 3.5-
heptad (3.5h) in length, but also contained shorter/longer peptides to provide 
competition for 3.5h members (see Figure 2). Based on MiSeq deep sequencing data 
of >5 million peptides (of which 99.9 % of were found to be unique), 39 % of peptides 
were 3.5-heptads in length, with 17 % of peptides longer and 44 % shorter than 3.5h; 
of the latter, 20 % comprised either single or dinucleotide deletions, or were missing a 
single codon (see SI). This mixed-length library was designed to include highly diverse 
sequences while simultaneously varying the length of the peptide to probe the ability 
of smaller sequences to compete effectively against larger sequences predicted to 
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form more points of contact with the target. In particular, this library probed whether 
a peptide shorter than a previously-derived binder, FosW 11, could be selected. 
Moreover, the CIS→PCA was employed to deliver a proof of principle of this technique, 
providing a range of peptide lengths and therefore expected affinities. The theoretical 
diversity of the library, designed to extensively explore functional space, was 7.3 x 1017, 
and therefore exceeded the maximal screening capacity of CIS display 23. However, to 
demonstrate CIS→PCA feasibility, the primary focus was to screen a highly diverse 
library containing a high probability of cJun binding peptides, such that partial library 
coverage was satisfactory. Using FosW as a design scaffold, library design options were 
based on those commonly found in the CC domains of bZIP proteins (Figure 2). Library 
construction utilised the ProxiMAX codon-by-codon randomisation technique, which 
avoids peptide-encoding redundancy, bias for selection of overrepresented peptides, 
and subsequent loss of library diversity 28. Construction of 3.5h peptides comprising N-
terminal truncations of FosW were rationalised on the basis of poor helicity as 
evidenced by in silico analysis of per residue helical propensity using the Agadir 
algorithm (Figure S2) 29, and the expectation that a cJun binder would require 
appreciable helicity in order to be dimerisation competent 18, 30.  
The CIS display library contained residue options to promote and maintain the 
parallel dimeric CC motif 31, together with some more unusual options. For example, 
at core a positions, hydrophobic options (I/L/V) were combined with aromatic residues 
(F/W/Y; 5% total frequency). These options were mirrored at d positions, which had 
been fixed as Leu in all other PCA screens against AP-1 to date 11, 27, 32 and randomised 
here to provide further diversity. These options were hypothesized to provide an 
increased opportunity to select residue contacts that maximise binding enthalpy and 
can therefore compensate for diminished length within shorter peptides, provided 
bulky side-chain packing could be facilitated. The library a2 position was fixed as Asn 
to provide parallel homotypic dimerisation with the cJun a3 Asn 33, 34. Charged/polar 
and atypical hydrophobic residues were offered at solvent-exposed b, c and f positions 
(E/K/R/Q/L/I/A) to provide opportunities to further promote helicity and solubility as 
well as further intra-molecular stabilisation via favourable sidechain–sidechain 
interactions 30, 35. Finally, e and g positions were given charged/polar (E/K/R/Q) options 
to promote interhelical interactions as well as solubility and/or helicity.  From this 
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library it was anticipated that a novel peptide sequence with high affinity for cJun 
would be selected. 
 
Library Screening Overview 
CIS display 22 and PCA 21 library display and selection systems were combined 
for the first time to allow high throughput and thorough screening of an expansive 
library to identify novel antagonists of cJun. The success of the approach was 
dependent on relevant selection pressures in the two systems being compatible such 
that peptides that bind cJun in vitro can also do so under in cellulo conditions. CIS 
display, cloning of CIS display hits into PCA vectors, and subsequent PCA screening of 
the remaining library (Figure 1) was considered the most accessible and facile strategy 
in this proof-of-concept trial, to achieve a simple combined system using standard 
molecular biology and microbiology techniques. 
 
Library Screening using CIS display  
CIS display screening of 6.1 x 1010 peptides meant that the number of 3.5h and 
4.5h peptides (2.4 x 1010 and 1.04 x 1010) was ≥10,000 fold larger than would be 
achievable with PCA alone (approx. 1.0 x 106). Library peptides were subjected to CIS 
display against an immobilised synthetic cJun CC region peptide, at two different 
selection stringencies (‘low’ and ‘high’ amounts of target presented to the expressed 
peptide library) to cover a range of possible peptide affinities for the target. CIS display 
selection efficacy was monitored using deep sequencing of the recovered DNA and 
resulted in 25,000-72,000 unique sequence reads from each of the two stringencies 
(recovered after panning rounds 3 and 4). Of these, 85–131 peptides were observed 
≥50 times and therefore considered to be sufficiently enriched for further analysis. 
 
 
 
Library Screening using PCA 
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The enriched clonal output from the library was subcloned into the PCA system 
(see SI). This resulted in extensive (≥95 %) coverage of remaining peptide diversity, as 
determined by counting colonies of transformed cells (see SI, Equation 1), to allow any 
peptide to be selected by PCA regardless of rank within the CIS display enrichment. 
Initially, PCA consisted of Single-step selection on minimally nutritious M9 medium 
plates. Following this, sequential passaging of cells in M9 minimal media was 
performed to provide Competition Selection. This further narrowed the pool of 
selected peptides to a single sequence by amplifying subtle differences in target 
affinities between peptides to drive selection of the highest affinity binder 21. Both 
approaches require library–target interaction and concomitant refolding of mDHFR for 
bacterial growth and peptide selection.  
PCA screening that followed low stringency CIS display selection rapidly isolated 
a single peptide from the ~25,000 library members to enter from the CIS display screen. 
The peptide, named ‘CPW’ (CIS→PCAWinner), was identified via Sanger sequencing. 
Reassuringly, this peptide was found to generate the fastest growing colonies at the 
Single-Step selection phase, indicating the highest recombined mDHFR activity, and 
was also the monoclonal sequence to emerge after 2-5 rounds of Competition 
Selection (Figure S3). This sequence emerged as the overall CISPCA winner from 
position 71 in low stringency CIS display (panning round 4 deep sequencing) based on 
the observed frequency of hits.  
Interestingly, for the high stringency CIS display selection, CPW was not 
identified in the sequenced reads. Rather, the highest-ranking peptide after high 
stringency CIS display selection also afforded fastest colony growth to win the 
corresponding high stringency PCA Competition Selection. This peptide (named “CIS1”) 
was also the highest ranked during low stringency CIS selection, but was ultimately 
outcompeted by CPW in the following low stringency PCA. During the CIS→PCA 
process, sequencing data was used to follow selection efficacy (selection round fold-
enrichment) and in silico prediction algorithms were used to evaluate parameters that 
describe peptide-cJun binding capabilities (Table S5). Most of the enriched peptides 
from the low and high stringency CIS display selections did not survive the 
corresponding PCA, demonstrating the importance of transferring all peptides from CIS 
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to PCA. Only 4.5h (32mers + capping motifs = 37mers) library members emerged from 
PCA screens, supporting the hypothesis that only longer peptides, capable of forming 
a greater number of specific interactions or that are inherently more stable with cJun, 
are generally selected.  
 
CPW sequence analysis 
The residue selections in CPW infer interhelical interactions with cJun residues, 
as well as intrahelical interactions that stabilise the CPW helix into a parallel dimeric 
conformation with cJun (Figure 3). Evidence for this comes from the struturally related 
cJun-FosW structure that we have recently reported (PDB ID 5fv819), as well as the wild-
type cJun-cFos (PDB ID: 1fos39) interaction, and the fact that PCA selects for parallel 
dimeric interactions. Peptides adopting higher-order or multiple oligomeric states, or 
that display the incorrect helix orientation, are highly unlikely since PCA only enriches 
for peptides that align in a parallel orientation (owing to linker length) during selection 
and ensures that specific helices are dimeric. 
Given the library options provided and where reference data was available, the 
majority of selected core residues corresponded to those predicted to contribute most 
to the dimerisation free energy 36. For example, Ile was selected at three out of five a 
positions and also, interestingly, three out of five d positions. Also unusually, Phe was 
selected at position a4, where it packs against a’4 Ala. Phe has the potential to form 
van der Waals interactions with Ala; however, the contribution of this pairing to 
stability has not been studied, nor has to what extent this bulky side chain can be 
accommodated in a dimeric core 37. 
At e and g positions, three of five positions appear to form interhelical 
interactions, as expected. Residues selected at g1, e2, and g3 are expected to make 
interhelical contact, and e3 Gln could perhaps make contact with the cJun g’2 Gln, with 
these four positions featuring the most optimal residues for dimerisation free energy 
38. At the remaining e4 position, Glu is located opposite Thr, a combination that has not 
previously been scored but that is unlikely to make a large energetic contribution. 
Selection of Arg at g2 is located opposite Ala and therefore predicted to make only a 
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small contribution to dimerisation free energy. Arg may, however, participate in a 
stabilising g–a’ interaction with the a’3 Asn of cJun, as has been observed in the cJun-
cFos crystal structure39, where it functions to improve dimer stability. Alternatively, Arg 
may interact favourably with either the solvent or g3 Glu within CPW. This has been 
observed at the corresponding position within the cJun-FosW crystal structure19. The 
Asn-Asn pair that is predicted to aid dimeric specificity is preserved via selection of Asn 
from six alternative options at a3 in the cJun-CIS1 peptide but lost in cJun-CPW, where 
Ile was selected.  
Possible intrahelical interactions between b, c and f residues could contribute 
favourably to dimerisation free energy, as well as more generally to CPW solubility and 
α-helicity, through stabilisation in a helical conformation. An expected preference for 
Glu, Lys, Gln, Arg and Ala rather than Ile or Leu was observed, with predominance of 
Gln (seven positions) over Glu (three positions), Lys (two positions) and Ala (one 
position), and no instances of Arg. The single Ala residue at b4.5 may aid helicity in this 
poorly helical region of CPW (Figure S2) 30, whilst other selections in these positions 
require future investigation. 
 
CPW–cJun in silico prediction 
In silico algorithms were used to predict the likelihood of the CPW–cJun 
interaction, and whether this complex is anticipated to form a CC rather than an 
alternative binding mode (Table S5). These predictions were compared against those 
for previously identified cJun-binders, and against CIS1–cJun to identify the highest 
affinity binder. Predictions by these algorithms are scaled to real, measured 
interactions between analogous sequences, and thus provide a more representative 
global view of interaction capability than can be gained from manual comparison of 
pairwise interaction preferences. Agadir 29 predicted 15 % helicity for CPW, lower than 
that of FosW (26 %), 4hFosW (22 %) or FosWCANDI (22 %), but much higher than native 
cJun binders (e.g. cFos = 3.5 %) and CIS1 (5.4 %), indicating potential for increased 
affinity for cJun (see also Figure S2). bCIPA 11 was used to predict the interaction 
stability of CPW–cJun, and calculated a Tm value of 53 °C. This value indicated promising 
potential for high affinity (nM) binding, and reassuringly was well above natural AP-1 
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CC interaction affinities (Tm values -4 °C to 18 °C ). CIS1 on the other hand was 
predicted to interact less favourably (Tm 44 °C). Finally, Base Optimised Weights (BOW) 
40 similarly predicts favourable CPW–cJun interaction relative to known binders and 
CIS1. 
 
CPW–cJun Characterisation 
Following solid-phase synthesis and purification, In vitro biophysical 
characterisation of cJun binding was performed using circular dichroism (CD) 
spectroscopy and isothermal titration calorimetry (ITC) to assess helicity, binding mode 
and interaction affinity.  
 
Circular Dichroism Experiments 
CPW demonstrated high affinity binding to cJun in vitro to form a CC as 
monitored by CD using 150 μM total peptide concentration. As confirmed from CD 
scans (see Figure 4B, Table 1), CPW was found to form a heteromeric complex with 
cJun, displaying a strong α-helical signature with characteristic minima at 222 and 208 
nm. The 222:208 ratio was indicative of formation of a CPW–cJun CC (222:208 ratio 
>0.9, 53% helicity) 41, 42. Moreover, the heteromeric CD trace far exceeded the non-
interaction calculated average of homomeric CPW CCs (slightly more helical than CPW–
cJun) and cJun alone (mixed random coil and helical spectrum), which together with 
ITC data provides firm evidence for the CPW–cJun interaction. 
CPW or CPW:cJun mixtures were subjected to thermal denaturation and the CD 
signal monitored at 222 nm for loss of helical structure. Both provided cooperative 
thermal denaturation profiles indicating formation of a CC structure (Figure 4), fitting 
extremely well to a two-state unfolding model 43. The highly helical CPW–cJun CC was 
thermally stable, with a Tm of 63 °C, displaying a higher Tm, lower Kd and more 
favourable ΔG than the respective CPW homotypic interaction. The CPW–cJun thermal 
denaturation profile far exceeded the non-interaction average with regard to helicity 
as well as the calculated Tm. CPW displayed higher helicity (+22 %) and a much higher 
Tm (+29 °C) than CIS1, supporting CIS→PCA low stringency selection of CPW over CIS1. 
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The thermal stability of CPW–cJun compares favourably with CCs of previously derived 
cJun antagonists (Table 1): the FosW–cJun Tm is identical to that of CPW–cJun, whilst 
that of 4hFosW–cJun and FosWCANDI–cJun are less stable than CPW–cJun by 14 °C and 
11 °C respectively. Compared to the native cFos–cJun AP-1 complex, CPW–cJun is more 
stable by 47 °C, indicating that inside the cell, CPW would be able to outcompete cFos 
(or indeed any other Fos/Jun family proteins) to create stable complexes capable of 
preventing cFos–cJun AP-1 formation. 
 
Isothermal Titration Calorimetry 
Isothermal titration calorimetry (ITC) experiments were used to more 
accurately evaluate binding free energy and deconvolute binding into component 
enthalpic and entropic contributions 27, 44, 45 (Figure 4 and Table 1). ITC further 
confirmed the CPW–cJun interaction; titrating cJun into CPW elicited the expected 
sigmoidal binding curve of a high affinity interaction, with the fit deriving a Kd of 750 ± 
270 nM. This translates to a ΔG of -8.2 ± 0.21 kcal/mol at 20 °C. Enthalpic contributions 
to ΔG dominated binding (-7.4 ± 0.67 kcal/mol) relative to the entropic term (0.81 ± 
0.81 kcal/mol). These values fit comfortably into the range previously observed for 
related CC interactions with cJun, including FosW11 (45 nM), 4hFosW27 (480 nM) and 
cFos (26.6 μM), and the enthalpically-driven CPW–cJun interaction is typical of CCs 27, 
46. Indeed the predominance of the enthalpic component to CPW–cJun interaction 
suggests that enthalpy is the dominant driving force for library peptide interaction with 
cJun, and hence why a 4.5h winner rather than a shorter peptide was selected. CPW 
displayed a 34-fold lower Kd by ITC than CIS1, again supporting its selection by 
CIS→PCA. Compared to the successful FosW–cJun interaction, the ΔG indicates high 
affinity for cJun suggesting that CPW, like FosW and 4hFosW, would be expected to 
outcompete cFos for cJun in cellulo to represent an effective antagonist of cFos–cJun 
AP-1 formation. 
 
 
DISCUSSION 
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In vitro and in cellulo library screening approaches have been combined for the 
first time, by using CIS display and PCA, with the aim of assessing whether together the 
attributes of both systems would constitute an effective system for identification of 
novel AP-1 antagonists. It was expected that, if compatible, CIS→PCA would benefit 
from considerable overlap in the capabilities to surmount shortcomings of the isolated 
respective systems, leading to cJun antagonists with attractive cellular stability isolated 
from extremely large peptide libraries. A disadvantage of in vitro systems is the 
likelihood of false positives that can result from non-specific interactions with other 
components of the assay. This can be partially overcome by addition of more target 
(‘low’ vs. ‘high’ stringency) and blocking agents, such as BSA. However, this results in 
lower primary selection stringency, and potentially reduced target affinities of winning 
peptides. In vitro systems can also potentially lead to enrichment of non-specific (often 
highly hydrophobic) binders due to the presence of non-target molecules. CIS→PCA 
allows initial selection of a library under relatively low stringency conditions (CIS 
display), thereby retaining valuable binders by avoiding requirement for unattainably 
high affinity, and then subsequently increases selection stringency (PCA) to isolate the 
highest affinity binders in a cellular environment relevant for the selection of 
therapeutic characteristics. In fact, PCA inherently selects against non-specific binders 
as these do not afford rapid host cell growth through sufficient specific interaction with 
the target and mDHFR recombination 11. Therefore, it was expected that selection 
pressures in CIS display and PCA would complement each other to provide the most 
favourable elements of both systems when combined.  
In this study, the ‘low stringency’ CIS selection conditions employed appear to 
have been more optimal for the affinities of peptides within the screened library. This 
generated a primary selection stringency that was appropriate to enrich the CPW 
peptide sufficiently such that it could be transferred to PCA and demonstrate specificity 
of binding in this assay. Conversely, the ‘high stringency’ CIS condition likely created a 
primary selection stringency too high for peptide affinities, leading to the inferior CIS1 
being selected as the best binder. It is also possible that CPW was not sampled in the 
‘high stringency’ CIS condition. The low stringency CIS condition corresponded to cJun 
at a solution concentration of 290 nM, such that peptides with Kd values ≤290 nM 
would be expected to be selected. Compared to the 750 nM Kd of CPW and 25 μM Kd 
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of CIS1, this suggests that the stringency of this selection could be lowered further in 
the future to limit potential loss of peptides that could otherwise demonstrate 
desirable affinity and specificity in PCA. Prior to this study it was unknown whether 
selection conditions for peptides against a target were sufficiently different during in 
vitro and in vivo systems to preclude their successful combination. Here we 
demonstrate for the first time that a cell-free in vitro (CIS display) and in cellulo (PCA) 
library display system can be effectively combined to derive high affinity cJun binders 
such as CPW from very large libraries of relatively small peptides. 
Construction of the CIS→PCA library resulted in a high diversity library of 
varying length through the modular construction of DNA corresponding to individual 
heptads. This meant that longer peptides could be preferentially selected over those 
with fewer residues by forming more points of interaction with the target (and thus an 
increased interaction affinity). CIS display enrichment of predominantly 4.5 heptad 
peptides, and the CIS→PCA selection of CPW, also a 4.5 heptad peptide, supports this. 
This corroborates the idea that affinity is spread along the length of the cJun interface, 
making identification of shorter peptides of high affinity more challenging19. It is 
further supported by the dominant role that enthalpy plays in the interaction affinity 
of CPW–cJun, as with many coiled coils 27, 46.  
The initial library was designed to identify an alternative template to FosW for 
further peptide development efforts, and to probe the favourability and function of 
aromatic residues at core positions, while offering options that might aid stability, 
solubility and helical propensity at poorly understood b, c and f positions. CPW 
represents such an alternative template, whilst selection of a Phe residue at the a4 
position of CPW and selections at b, c and f residues will contribute to our growing 
knowledge of the structural and sequence determinants of CC formation, which can be 
exploited in the design of new libraries for selection of modulatory peptides of disease-
related CCs. CIS→PCA creates exciting prospects for future assay development and 
refinement. Combining the two approaches brings additional stringency and the ability 
to isolate individual sequences via competition selection within cells. This is expected 
to significantly reduce the number of lead molecules to emerge, with those that do 
predicted to display improved therapeutic properties. CIS→PCA also has the 
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considerable potential to provide an accessible and attractive alternative to powerful 
but complex in vivo phage display (biopanning), where library peptides are selected for 
affinity and desirable drug-like properties through administration to animal disease 
models 47. In the future, the concept of CIS→PCA could be translated to combination 
of an in vitro selection system with yeast two hybrid or other cell-based selection 
systems more tailored towards expression of eukaryotic proteins of more complicated 
post-translational modifications. This would further broaden the applications and 
benefits of CIS→PCA to make it an even more valuable selection strategy.  
 
CPW as a novel AP-1 antagonist 
The affinity of CPW for cJun is similar to that of FosW and 4hFosW, but novel 
and non-canonical in sequence, which may yet provide useful design features for future 
antagonists. The affinity of CPW is lower than that of computationally designed Jun-d1 
and peptide-DNA conjugate C2ds (6 nM and 362 nM as determined by solution 
fluorescence resonance energy transfer and fluorescence anisotropy), and A-Fos, a 
bZIP CC peptide with an acidic extension (0.03 nM as estimated by CD thermal 
denaturation), assuming the equivalence of different biophysical techniques. However, 
the advantage of CPW is its small size; at 37 residues (32mer plus five residues of helix-
capping motifs), CPW is shorter than Jun-d1 by five residues, similar in length to 35mer 
C2ds but lacking 18 bp of conjugated dsDNA, and is shorter than A-Fos by 26 residues. 
Accordingly, the affinity of CPW for cJun compares well with these molecules when 
antagonist length is taken into consideration, whilst being of a smaller size that may be 
more attractive for further therapeutic development.  Modifications to improve 
desired properties while decreasing the molecular weight might include the 
introduction of helix-inducing constraints at solvent exposed regions to allow further 
downsizing without loss of intrinsic helicity 18. Finally, compared to T-5224, a small 
molecule DNA-binding inhibitor discontinued at Phase II clinical trials and 
demonstrating an in cellulo IC50 of approx. 10 μM 48, the in vitro affinity of CPW is 
>13,000 greater, making it a promising candidate for in cellulo efficacy at least akin to 
that demonstrated for T-5224. Further, by targeting the CC domain of cJun rather than 
the DNA-binding domain – which is highly homologous to other bZIP transcription 
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factor families 49 49, 50 – CPW could be more specific to cJun-containing oncogenic AP-1 
compositions than T-5224. 
 
CONCLUSION 
The CPW peptide was selected from a library of 6.1 x 1010 peptides, one of the 
largest libraries screened against cJun to date. In the example presented here, CIS 
display selection was able to very effectively reduce the library size from 1010 to 
approximately 105, making this narrowed pool very accessible to further screening via 
PCA, which ultimately identified CPW as the highest affinity binder (Kd 750 nM) with in 
cellulo activity. In comparison, the best peptide candidate from CIS display alone (CIS1 
- highest ranked peptide in high and low stringency CIS display) displayed a 34-fold 
weaker Kd for cJun. The superior binding of CPW relative to top-ranked peptides 
selected by CIS display alone thus supports the original hypothesis that CIS→PCA 
combination may represent a more attractive system than CIS display or PCA alone. 
Moreover, the results described here suggest that inside the cell CPW can outcompete 
cFos for cJun to antagonise cFos–cJun formation and AP-1 oncogenic activity. Further 
investigation and development of this peptide, as well as refinement of CIS→PCA, 
could generate valuable antagonists for the future therapy of cancers featuring AP-1 
dysregulation, or aid in the development of other modulatory peptides towards this 
goal. 
 
METHODS 
Library construction by ProxiMAX 28, CIS display 22 and PCA 21 were performed as 
previously described, with minor modifications detailed in the SI. CD spectroscopy was 
performed on the winning peptide alone or a 1:1 stoichiometric mixture of 
peptide:cJun at 150 μM total protein concentration (Pt) in potassium phosphate 
without potassium fluoride (“low salt”) buffer. Raw ellipticity was converted to mean 
residue ellipticity (MRE; deg cm2/dmol) to normalise for different peptide lengths and 
concentrations as described previously (see SI). ITC was performed by injecting 620 μM 
cJun into 70 μM winning peptide again in “low salt” buffer. Change in heating power 
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(μcal/sec) with each injection was integrated to generate binding isotherms, from 
which ΔH, ΔS, ΔG and Kd values were derived by non-linear least-squares fitting as 
described previously using Origin software (OriginLab, MA, USA) (see SI).  
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Figure 1: CIS→PCA. Library construction and selection of cJun binding peptides by 
sequential CIS display and Protein-fragment Complementation Assay (PCA) 21, 22, 28. 
Black arrows indicate the path of progression through CIS→PCA. CIS display and PCA 
schematics adapted from sources. For further details of ProxiMAX, CIS display and PCA, 
see SI and Figure S1. 
Figure 2: Peptide library design. The mixed length library was built in a modular fashion 
from DNA corresponding to Heptad 1, 2 and 4.5 cassettes (each is underlined) 
constructed using the ProxiMAX codon-ligation approach28. Within each cassette, 
codons corresponding to amino acids were incorporated at equal frequencies, except 
aromatic residues F, W and Y, which were introduced at a total frequency of 5 % (split 
equally). Heptad positions are in bold italics, library theoretical diversity is in bold text. 
Note that for internal heptads, 1-3 copies of the Heptad 2 library module were use to 
create the highly diverse mixed-length peptide library.  
Figure 3: Possible interactions stabilising a dimeric CC interaction between CPW and 
cJun. A DrawCoil helical wheel diagram51. Core interhelical a–a’ and d–d’ interactions 
are shown as black arrows, and expected stabilising interhelical ei–g’i-5 and gi–e’i+5 
interactions are shown as blue dashed lines. A possible interhelical polar-polar 
interaction (e3–g’2 Q–Q) is shown as an orange dashed line. All possible i→i+3 and 
i→i+4 intrahelical interactions between outerface b, c and f residues (some mutually 
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exclusive) are displayed with orange dashed lines. Possible intrahelical interactions 
between outerface residues and e and g residues are not shown. Residues are coloured 
grey for hydrophobic, red for positively charged, orange for polar, and blue for 
negatively charged. B Linear sequence view of helical wheel diagram in A. Heptad 
register shown in italics. C Contributions to interaction ΔG from selected residues in 
CPW assuming interaction with cJun residues, with Ala–Ala as the reference state 
(mimicking no selection). ΔΔG energies from Acharya et al.36 and Krylov et al.38, with 
two values depending on residue orientation. ND = not determined. 
Figure 4: CIS→PCA selected CPW binds cJun with high affinity, and higher affinity than 
CIS display selected CIS1. Biophysical characterisation of CPW or CIS1 alone and with 
cJun by CD spectroscopy scans (A and D) and thermal denaturation (B and E), and ITC 
(C and F). CD data is reported as change in mean residue ellipticity (MRE; units deg cm2 
dmol-1, to allow for comparison between peptides of different lengths), as a function 
of CD ellipticity over the wavelength range 200 – 300 nm or at 222 nm with 
temperature. Peptides interact with cJun where MRE and/or melting temperature (Tm) 
for peptide:cJun mixes exceed that of the calculated average trace of peptide and cJun 
only traces (which represents non-interaction). ITC raw isotherms (top panels) and 
fitted data (bottom panels) (both baseline corrected). On the fitted data plot, the solid 
line represents the fit generated by non-linear least-squares fitting. See 19 for equations 
using for fitting. 
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Table 1: CPW displays high affinity binding to cJun, similar to that of previous cJun antagonists, substantially higher than native 
cFos, and higher than CIS display selected CIS1. 
 
 
Thermodynamic parameters for CPW in interaction with cJun compared to cJun antagonists FosW46, 4hFosW27, and FosWCANDI32, and native cFos. CPW is also compared to less successful CIS→PCA high stringency winner CIS1, the 
most frequent peptide in CIS high and low stringency selection. Data from CD and ITC measurements. θ is raw CD ellipticity (mdeg). Fractional helicity was calculated as previously19. TΔS is calculated as ΔH – ΔG from the Gibbs-
Helmholtz equation (see19). CD values are from representative single measurements, typically reproducible in biological replicates to ± 1 °C for Tm, within 5 % for fractional helicity and 222:208 ratio (θ222/208), and within 10 % for 
Kd and ΔG (data not shown). ITC values are the arithmetic mean of two to three independent titrations ± SDs, except values for 4hFosW–cJun, FosWCANDI–cJun and cFos–cJun (single titrations and fitting errors). *’low salt’ buffer (10 
mM KH2PO4/K2HPO4, no KF), other peptides assayed in KPP buffer (“low salt”+ 100 mM KF). “ND” = not determined. Values given to 2 s.f.. ^Indicates a discrepancy between CD and ITC derived Kd values; for all comparisons the 
more accurate ITC derived Kd  has therefore been adopted.  
Complex 
Tm 
(°C) 
(CD) 
Peptide–cJun 
Fractional Helicity 
(%) (CD) 
Kd(20°C) 
(nM) 
(CD) 
∆G(20°C) 
(kcal/mol) 
(CD) 
Kd(20°C) 
(nM) 
(ITC) 
N interaction 
stoichiometry 
(ITC) 
∆G(20°C) 
(kcal/mol) 
(ITC) 
∆H(20°C) 
(kcal/mol)    
(ITC) 
T∆S(20°C) 
(kcal/mol) 
(ITC) 
Peptide–cJun 
Ɵ222/208 
(20°C) (CD) 
cFos–cJun 16 28 320,000 -5.5 27,000 1.1 ± 0.01 -6.1 ± 0.39 -0.82 ± 0.36 5.32± 0.53 0.75 
FosW–cJun 63 37 4.0 -11 39 ± 11 0.99 ± 0.08 -9.9 ± 0.16 -10 ± 0.42 -0.46 ± 0.46 1.0 
4hFosW–cJun 49 60 490 -8.5 480 1.1 ± 0.01 -8.8 ± 0.10 -14 ± 0.20 -5.3 ± 0.20 0.99 
FosWCANDI–cJun  52 54 ND ND ND ND ND ND ND 1.0 
CPW–cJun* 63 53 0.27^ -13 750^ ± 270 0.48 ± 0.03 -8.2 ± 0.21 -7.4 ± 0.67 0.81 ± 0.81 0.95 
CIS1–cJun* 34 31 14,000 -6.5 25,000 ± 13,000 0.11 ± 0.02 -6.2 ± 0.29 -15 ± 4.42 -9.2 ± 4.6 0.71 
